>>> US Gapping up

Gapping up
In reaction to earnings/guidance:

HLF +19.8% (also names new CEO), LUNG +16%, CWAN +15.9%, AMPL +15.5%, NRDS +10.2% (also names new CFO), BABA +10%, BMRN +9.7%, MCW +9.6%, BILI +9.5%, SWTX +9.5%, MD +7.9%, PWR +7.2%, LYG +6.4%, AHH +6.3%, RELY +5.4%, CSTM +5.3%, CHH +4.9%, FPI +4.8%, BHC +4.6%, CCJ +4.4%, ATHM +3.6%, OEC +3.3%, SGI +3.3%, CNR +3%, LKQ +2.8%, ICLR +2.7% (also authorizes new $750 mln share repurchase program), VALE +2.6%, ANSS +2.5%, CIB +2.4%, PLL +2.4%, HAS +2.3%, TRN +2.3%, NOG +2.2%, ULS +2.2%, UTZ +2.1%, TNK +1.8%, MFC +1.7% (also increases dividend), TRIP +1.7%, JXN +1.6% (also increases dividend), PAAS +1.6%, BIGC +1.6%, IIPR +1.5%, NTR +1.4% (also increases dividend), VAL +1.4%, NGD +1.4%, ESRT +1.3%, SBRA +1.3%, LILA +1.2%, OGS +1.2%, AGI +1.1%, SM +1%, RGR +1%

Other news:

FTAI +13.9% (Audit Committee completes independent review, expects to file 10-K timely)
ZBIO +4.5% (CEO bought 25,000 shares)
NMRK +2.9% (provides Cantor (controlling stockholder) update)
HAS +2.3% (unveiling a new strategic plan, 'Playing to Win' taking the company through 2027)
PDFS +2.2% (to acquire secureWISE)
IONS +2.2% (announces that it will present additional data from the pivotal Phase 3 OASIS and OASISplus studies, as well as three year data from the Phase 2 open-label extension study of donidalorsen)
APLS +1.4% (Apellis Pharmaceuticals and Sobi receive EMA Validation of Indication Extension Application for Aspaveli)
AESI +1.3% (increases dividend)
ONB +1% (authorizes new $200 mln share repurchase program)

Analyst comments: